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TUMOUR MARKERS have been investigated
for over 20 years as a possible means of
early diagnosis or assessment of response
to treatment. In a number of cases-
choriocarcinoma, teratoma, adenocar-
cinoma ofthe colon certain markers have
been of value in assessing therapeutic
responses and for the detection of tumour
recurrence. No marker is yet specific
enough to assist in early diagnosis.
Teratoma of the testis can produce two
markers-human chorionic gonadotrophin
(HCG) and Alpha-foetoprotein (AFP);
seminoma, on the other hand, is not
known to produce a chemically useful
marker.
It has been known for many years that
serum lactate dehydrogenase (LDH) is
elevated in patients with bulky metastatic
disease (Brindley & Francis, 1963: Hill &
Levi, 1954). This nonspecific marker has
not been widely used as it is produced by
numerous tumours (Goldman et al., 1964).
Recently however it has been suggested
that isoenzyme I of LDH may be of value
as a marker for testicular tumours
(Wampler & Hayra, 1977). In this paper
evidence is presented that serum LDH
may be of value in identifying patients
with advanced seminoma once the diag-
nosis of seminoma is confirmed, and in
assessing the response of patients to
treatment.
Thirty-six patients with seminoma of
the testis were referred to the Christie
HBospital and Holt Radium Institute over
an 8-month period. Thirty-two patients
had had an orchidectomy performed at
another hospital, 2 patients had had a
laparotomy and one patient a biopsy ofan
inguinal node. In one patient the orchi-
dectomy was carried out at the Christie
Hospital. This latter patient and one other
with advanced disease were seen before
surgery. All others were referred after
surgery. The pathological material was re-
examined in every case. These patients
were assesse(I for the presence of certain
tumour markers in their serum. Two
further patients who had relapsed after an
earlier treatment and who were treated
during this period are also included in the
study. All patients had chest radiology
and i.v. urography. Computer-assisted
tomography was performed only in
patients in whom there was clinical or
radiological suspicion of para-aortic
disease.
The staging system used at the Christie
Hospital is shown in Table I. Patients with
a normal IVU on admission did not have a
CAT scan of abdomen, as already stated,
nor was lymphangiography carried out on
these patients. Patients with minimal
involvement ofabdominal or pelvic lymph
nodes cannot be differentiated from those
with no disease. Those with Stage I and
Stage IIA disease are therefore grouped
together as "early" disease. In 3/27 cases
with "early" disease there were tumour
cells at the cut end of the cord so that at
least 3 patients had Stage IIA disease. The
distribution ofpatients by stage was thus:
"early" (including Stage IIA), 27 patients;
Stage JIB, 5; Stage III, 3; and Stage IV, 3.
Patients with early disease received
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TABLE I. Christie Hospital: Staging of
testicular tumours
I Disease coinfined to the testis
IIA Abdominal no(les ii-nvolve(d but
impalpable
lIB Abdlomirnal nodes iinvolved afli(
palpable
III Supradiapliragmatic nocdes
involve(d
IV Extranodal involvement.
"Early"
"Late"
radiotherapy to the para-aortic and iliac
nodes and scrotum. A central midplane
dose of 3,000 cGy in 20 fractions over 28
days was given using a 4 or 8 MV linear
accelerator Gibb (1960). Patients with
Stage IIB disease were treated with a
larger abdominal field initially and shield-
ing of at least one kidney was introduced
when a central midplane dose of 1,500 cGy
was reached. The treatment was then
continued to a dose of 3,000 cGy in 4
weeks.
Patients with Stage III or IV disease
were assessed individually and treated
with either radiation or combination
chemotherapy. Patients in whom there
was evidence ofmetastatic disease initially
were re-assessed at 3-4 months after
treatment using chest radiology and
computer-assisted tomography. Further
treatment with either radiotherapy or
chemotherapy was given if there was
residual disease.
All patients with early disease are alive
and apparently disease-free. Of the
patients with IIB disease 4 were found to
be in remission at re-assessment. The
remaining patient was found to have a
supraclavicular node 6 weeks after radio-
therapy in addition to residual abdominal
disease. He was treated with combination
chemotherapy and is in complete
remission.
Of the Stage III patients, 2 receivecl
radiotherapy and are in remission, while
the third received chemotherapy and is
having radiation to residual disease. One
Stage IV patient died immediately after
radiotherapy, another received chemo-
therapy and the third received chemo-
therapy after failure to respond to
radiation but has progressive disease.
AFP and HCG were measured by radio-
immunoassay. The HCG assays were
performed at Charing Cross Hospital and
AFP was assayed at the Regional Labora-
tories in Manchester. The enzymes LDH,
y-glutamyl transferase (GGT), alkaline
phosphatase (Alk P), aspartate transferase
(AST) and alanine transferase (ALT) were
assayed in the routine biochemistry labor-
atory atWithington Hospital, Manchester.
Ten ml of clotted blood were collected
from the patient on admission for radio-
therapy before his first treatment. Control
levels were those previously established by
the Biochemistry Laboratory at Withing-
ton. No attempt was made to study the
levels ofthe different isoenzymes ofLDH.
The study was partly retrospective.
Some assays were not carried out on all of
the patients (Table II). Seven markers
were evaluated for the detection of bulk
disease and, in the case of LDH, for the
assessment of response to treatment
(Table II).
AFP was elevated in 1/30 cases. This
patient had liver metastases. HCG was
elevated in 5/31 cases all of whom had
advanced disease. Three patients with
advanced disease, however, had normal
levels. An elevated level did not signify a
poor prognosis.
Four enzymes, GGT, Alk P, AST and
ALT were also assessed as potential
markers. Table (II). Nine of 37 patients
had elevated Alk P levels. Two of the 9
cases had early disease. Two patients with
advanced disease had normal values. Two
of 37 patients had elevated AST levels, one
of these had early disease. Nine patients
with advanced disease had normal levels.
Six of 37 patients had elevated levels of
ALT levels. Four of six patients had
"early" disease. Two of 38 patients had
elevated y-GGT levels. Both patients had
advanced disease. Nine of 1 patients with
advanced disease had normal levels.
Of the 7 markers assessed LDH
appeared to be the only one ofvalue. None
ofthe 27 patients with "early" disease had
995A. G. ROBERTSON AND G. READ
elevated values. Nine of the 11 patients
with advanced disease had values out with
the normal range (Fig. 1) and one was
borderline. The patient with a normal
LDH level and advanced disease presented
with arecurrence.
In 10/11 advanced cases LDH was
monitored during treatment and subse-
quentfollow up (Figs 2, 3 & 4). In 7 cases
the level returned to normal following
initial treatment and subsequent investi-
gation revealed complete resolution of
disease. In 3 cases radiotherapy failed to
control the disease and bring the LDH
level into the normal range; all had clinical
evidence of residual disease. One of these
patients died, 2 responded to further
treatment (chemotherapy) although one
has residual disease. In one patient on
follow-up a raised LDH level was noted 2
months before mediastinal adenopathy
becameradiologically apparent.
This study was initiated when one ofour
patients with Stage IV disease was found
to have grossly elevated LDH levels, while
other liver and cardiac enzymes were
normal. It utilized established assays for
enzymes and tumour markers which are
readily available to the clinician at routine
regional and supra regional laboratories.
Of the 7 markers evaluated in the
present study on 38 patients, only LDH
showed anassociationbetweenraisedlevels
and advanced disease. No attempt was
made to identify any of the individual
isoenzymes of which the LDH is
composed.
AFP was elevated in only one case out
of 30 and this patient had extensive liver
involvement. It is suggested that AFP
should be routinely determined in all
patients with testicular tumours at first
presentation. However, if the intial value
is normal and the pathological diagnosis is
seminoma then subsequent estimations are
unhelpful.
Approximately 16% of those in whom
HCG was estimated had elevated levels.
All the patients with elevated levels had
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FIG. l.-Scattergram showing how the LDH level
varies with stage of disease.
TABLE II.-Relative value of tumour markers in seminoma
Marker
LDH
AFP
HCG
Alanine transaminase
Aspartate transaminase
Alkaline phosphatase
y-Glutamyl transferase
Number ofpatients Median value
38 388
30 <12
31 < 1
37 25
37 26
37 73
38 35
Range*
116-11,440 (500)
< 12-41 (25)
< 1-254 (10)
7-240 (40)
6-99 (50)
40-202 (92)
9-185 (118)
* Figures in parentheses denote upper limit of normal.
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advanced disease. An elevated level did
not necessarily signify a poor prognosis
though 2 of the 3 patients with grossly
elevated levels did not respond to treat-
ment and subsequently died. Marginal
elevation ofHCG may be insignificant but
gross elevation (> 100 i.u./l) may be a poor
prognostic sign and an indication that the
first line of treatment should be
chemotherapy.
The four enzymes, GGT, Alk P, AST
and ALT proved to be of no value as
potential markers (Table II). Elevated
levels of these enzymes were not necess-
arily an indication ofadvanced disease.
LDH has been known for many years to
be elevated in patients with metastatic
disease (Hill & Levi, 1954). It is also
elevated in patients with viral hepatitis,
cirrhosis, biliary tract disease and myo-
cardial infarction. As a nonspecific indi-
cator of bulk disease, LDH has been
studied in patients with colorectal cancer
(Beck et al., 1979), gastric cancer (Carda-
Abella et al., 1978), uterine cancer
(Marshall et al., 1979) and testicular
tumours.
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FIG. 2.-LDH levels of 3 patients with Stage
IIB disease during and after radiotherapy
to the abdomen.
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FIG. 3-LDH levels of patients with advanced
disease during and after treatment.
In the majority ofadvanced cases LDH
was estimated regularly during treatment
and thereafter on follow-up. In 4 of the 5
cases with Stage IIB disease the LDH
level returned to normal during treat-
ment; the results of3 ofthese are shown in
Fig. 2. The levels have remained normal
after completion oftreatment. In one case
in which the patient had IIB disease
(Fig. 3), the level fell initially with
abdominal X-ray treatment but did not
return to normal. It was assumed that the
patient had residual disease and a supra-
clavicular node was found at first follow-
up. Combination chemotherapy was
initiated and subsequent assessment has
shown complete remission with return to
normal ofthe LDH level.
Two patients with advanced disease
(Fig. 3) did not respond to treatment. In
one case XRT was stopped and chemo-
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FIG. 4.-LDH levels of patients with advanced dis-
ease during and after treatment.
therapy started. Initially the patient
responded and the LDH level fell. How-
ever, the tumour started to regrow before
the next course of chemotherapy was
given. In retrospect the time interval
between courses of treatment should
probably have been shortened.
This study thus illustrates that LDH
levels can be readily monitored during
treatment and follow-up. A return of
elevated levels to normal is a useful
indicator of response treatment. Con-
tinued elevation indicates the presence of
residual disease. A return to an elevated
level at a later time would indicate a late
recurrence.
LDH as measured in routine biochem-
istry laboratories is made up of 5
isoenzymes-the percentage of each iso-
enzyme may vary from patient to patient
depending upon the source ofthe majority
of the enzyme. Blanco & Linkman (1963)
reported a unique form of LDH in post-
pubertal testes and sperm. Goldberg
(1963) reported that the LDH-X ofBlanco
& Linkman was similar to LDH IV.
Despite the reports of high levels of LDH
IV/LDH-X in normal adult testes,
Wampler & Hayra (1977) reported that
LDH-1 was elevated in 2 patients with
testicular tumours. Marshall et al. (1979)
and Carda-Abella et al. (1978) have
recorded changes in isoenzyme patterns in
tumours arising at other sites. The 2
groups have suggested that the shift may
be due to changes in metabolism in the
tumour cells, possibly due to reduction in
available oxygen in bulky tumours. Varia-
tions in amounts of specific isoenzymes
may therefore only be an indication of
bulky tumours and not an indication of
the total tumour mass.
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